Seeking Alpha
 

Zoll Medical Corporation (ZOLL)

- NASDAQ
ZOLL is defunct since April 30, 2012. acquired by a private company
Show Summaries  |  Hide Summaries
  • Mar. 12, 2012, 9:00 AM
    Premarket gainers: TUDO +203%. KUTV +33%. ZOLL +24%. YOKU +20%. OREX +15%. FCEL +9%. RENN +9%. DANG +8%. SINA +4%.
    Losers: ANTH -51%. HGSI -4%. TLK -3%.
    | Comment!
  • Jan. 20, 2012, 3:56 PM
    SunTrust Robinson Humphrey rings in on Zoll Medical (ZOLL +5.5%) after its solid FQ1 result late yesterday, calling it a "phenomenal margin expansion story" and naming it as its top pick in the medical devices space. The firm expects its emerging businesses to rack up 30-40% growth over the next few years.
    | Comment!
  • Jan. 20, 2012, 9:58 AM
    Zoll Medical (ZOLL +5.8%) surges at the open following strong FQ1 results which showed revenue from its LifeVest wearable defibrillator worn by patients at risk for sudden cardiac arrest, jumped 45% to $32.3M and now accounts for 20% of revenue. Zoll seems back on track after the strong quarter and Medicare's recent reversal of a decision to change its coverage policy.
    | Comment!
  • Dec. 15, 2011, 10:47 AM
    Zoll Medical (ZOLL +11.7%) announces that CMS coverage for its LifeVest Wearable Defribrillator was reaffirmed after it received positive support across the cardiology-focused community. Shares will actively trade again at 11:00 AM EST after being halted.
    | 1 Comment
  • Dec. 15, 2011, 10:05 AM
    Trading on Zoll Medical (ZOLL) is halted pending a news announcement. Shares were up 11% before the stop in action.
    | Comment!
  • Nov. 17, 2011, 9:42 AM
    Zoll Medical (ZOLL) +18.8% at the open, after reporting FQ4 EPS of $0.52, vs. $0.33 in the year-ago period and better than analyst estimates of $0.49, and a 65% rise in profit on strong sales of its LifeVest device. The maker of defibrillators forecasts 2012 revenue will rise as much as 19% vs. analyst consensus of ~16%, and reports a $50M share buyback program.
    | Comment!
  • Aug. 8, 2011, 3:41 PM
    ZOLL Medical (ZOLL -24%) gets crushed after revealing it's facing a potential revision by Medicare over how much it will pay to cover the cost of the company's defibrillators, including its LiveVest product. The outlined cuts could have "a material adverse effect on its LifeVest business," the company says.
    | Comment!
  • Jul. 29, 2011, 11:46 AM
    Zoll Medical (ZOLL +25%) soars after FQ3 earnings easily blows out estimates. Revenues jumped 22% Y/Y, driven by higher defibrillator sales after larger hospitals - who have been sitting on the sidelines for the past couple of years - are stepping up purchases.
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for ZOLL.